Royalty Pharma is a buyer of biopharmaceutical royalties. The royalties in Co.'s marketed portfolio related to approved products include: cystic fibrosis franchise, which consists of Co.'s right to receive royalty payments on the sale of various products for use in the treatment of cystic fibrosis, including Kalydeco (ivacaftor), Orkambi (lumacaftor and ivacaftor), Symdeko/Symkevi (tezacaftor and ivacaftor) and Trikafta/Kaftrio (elexacaftor, tezacaftor and ivacaftor); and Tysabri, which is a monoclonal antibody for the treatment of relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.
RPRX SEC Filing Email Alerts Service
RPRX SEC Filing Email Alerts Service
|
|
Free RPRX Email Alerts: Get SEC Filing Alerts Get Dividend Alerts |
Strong Buy (3.79 out of 4) 71st percentile
(ranked higher than approx. 71% of all stocks covered)
Analysts' Target Price: RPRX Stock Forecast Based on Zacks ABR data; powered by Xignite |